Revenue
Quarterly revenue figures showing top-line growth.
Latest Revenue: $19.80B (2026Q1); +55.5% YoY.
Revenue
EPS
Free Cash Flow
Gross Margin
FCF Margin
P/E Ratio
Cumulative FCF
Shares Outstanding
Rule of 40
Quarterly Revenue Data
| Period | Value |
|---|---|
| 2024Q1 | $8.77B |
| 2024Q2 | $11.30B |
| 2024Q3 | $11.44B |
| 2024Q4 | $13.53B |
| 2025Q1 | $12.73B |
| 2025Q2 | $15.56B |
| 2025Q3 | $17.60B |
| 2025Q4 | $19.29B |
| 2026Q1 | $19.80B |
Healthcare Comparison
1 / 3
Other LLY Charts
More quarter-by-quarter fundamentals for Eli Lilly and Company
1 / 8